{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:19:29Z","timestamp":1789676369494,"version":"4.0.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T00:00:00Z","timestamp":1764288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["23K06678"],"award-info":[{"award-number":["23K06678"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K10336"],"award-info":[{"award-number":["24K10336"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Muscle-invasive bladder cancer (MIBC) is an aggressive malignancy with high recurrence and poor survival, accounting for the majority of bladder cancer\u2013related deaths. A subset of MIBC harbors\n                    <jats:italic>FGFR1<\/jats:italic>\n                    amplification or overexpression, associated with increased proliferation and poor prognosis. Although the pan-FGFR inhibitor erdafitinib has demonstrated clinical benefit in patients with\n                    <jats:italic>FGFR3\/FGFR2<\/jats:italic>\n                    alterations, primarily in non-MIBC, its efficacy is limited by resistance and toxicity. Moreover, its effectiveness in\n                    <jats:italic>FGFR1<\/jats:italic>\n                    -driven MIBC remains unclear. To address this gap, we investigated erdafitinib response and resistance mechanisms in JMSU1 cells, a model of\n                    <jats:italic>FGFR1<\/jats:italic>\n                    -amplified MIBC. While erdafitinib initially suppressed tumor growth, prolonged treatment led to resistance, characterized by persistent activation of ERK, AKT, and STAT1 signaling pathways. Mechanistic studies identified MET activation, driven by\n                    <jats:italic>MET<\/jats:italic>\n                    gene amplification, as a key driver of resistance. Notably, exogenous hepatocyte growth factor (HGF) not only induced resistance but also accelerated the emergence of\n                    <jats:italic>MET<\/jats:italic>\n                    -amplified, HGF-independent subpopulations under drug pressure. We also identified SHP2 as a critical mediator of FGFR1-driven ERK activation in parental cells. In resistant cells, MET activation enhanced SHP2\u2013ERK signaling through the adaptor protein GAB1, reinforcing the resistant phenotype. Combined inhibition of FGFR1 and MET significantly suppressed tumor growth in resistant cells. These findings establish\n                    <jats:italic>MET<\/jats:italic>\n                    amplification and GAB1\u2013SHP2 signaling as central mediators of erdafitinib resistance in\n                    <jats:italic>FGFR1<\/jats:italic>\n                    -amplified MIBC and support dual FGFR1\/MET targeting as a promising therapeutic strategy.\n                  <\/jats:p>","DOI":"10.1038\/s41419-025-08221-8","type":"journal-article","created":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T14:49:49Z","timestamp":1764341389000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["MET signaling drives acquired resistance to erdafitinib in muscle-invasive bladder cancer cells"],"prefix":"10.1038","volume":"16","author":[{"given":"Syunta","family":"Makabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoka","family":"Hoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Masuishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Yaginuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Meguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akifumi","family":"Onagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Hoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Shimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5352-173X","authenticated-orcid":false,"given":"Michiru","family":"Nishita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,28]]},"reference":[{"key":"8221_CR1","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00345-024-04949-8","volume":"42","author":"A Weber","year":"2024","unstructured":"Weber A, Vignat J, Shah R, Morgan E, Laversanne M, Nagy P, et al. Global burden of bladder cancer mortality in 2020 and 2040 according to GLOBOCAN estimates. World J Urol. 2024;42:237.","journal-title":"World J Urol"},{"key":"8221_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/s41585-018-0105-y","volume":"16","author":"B Jordan","year":"2019","unstructured":"Jordan B, Meeks JJ. T1 bladder cancer: current considerations for diagnosis and management. Nat Rev Urol. 2019;16:23\u201334.","journal-title":"Nat Rev Urol"},{"key":"8221_CR3","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nrclinonc.2016.188","volume":"14","author":"SA Funt","year":"2017","unstructured":"Funt SA, Rosenberg JE. Systemic, perioperative management of muscle-invasive bladder cancer and future horizons. Nat Rev Clin Oncol. 2017;14:221\u201334.","journal-title":"Nat Rev Clin Oncol"},{"key":"8221_CR4","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","volume":"22","author":"T Helsten","year":"2016","unstructured":"Helsten T, Elkin S, Arthur E, Tomson BN, Carter J, Kurzrock R. The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing. Clin Cancer Res. 2016;22:259\u201367.","journal-title":"Clin Cancer Res"},{"key":"8221_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1136\/jclinpath-2020-207115","volume":"74","author":"KI Al-Obaidy","year":"2021","unstructured":"Al-Obaidy KI, Cheng L. Fibroblast growth factor receptor (FGFR) gene: pathogenesis and treatment implications in urothelial carcinoma of the bladder. J Clin Pathol. 2021;74:491\u20135.","journal-title":"J Clin Pathol"},{"key":"8221_CR6","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/nrc2780","volume":"10","author":"N Turner","year":"2010","unstructured":"Turner N, Grose R. Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer. 2010;10:116\u201329.","journal-title":"Nat Rev Cancer"},{"key":"8221_CR7","doi-asserted-by":"publisher","first-page":"490","DOI":"10.20892\/j.issn.2095-3941.2023.0137","volume":"20","author":"S Du","year":"2023","unstructured":"Du S, Zhang Y, Xu J. Current progress in cancer treatment by targeting FGFR signaling. Cancer Biol Med. 2023;20:490\u20139.","journal-title":"Cancer Biol Med"},{"key":"8221_CR8","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.eururo.2024.09.012","volume":"87","author":"R Li","year":"2025","unstructured":"Li R, Linscott J, Catto JWF, Daneshmand S, Faltas BM, Kamat AM, et al. FGFR inhibition in urothelial carcinoma. Eur Urol. 2025;87:110\u201322.","journal-title":"Eur Urol"},{"key":"8221_CR9","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, et al. Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma. N Engl J Med. 2023;389:1961\u201371.","journal-title":"N Engl J Med"},{"key":"8221_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2025.102376","volume":"23","author":"N Matsubara","year":"2025","unstructured":"Matsubara N, Loriot Y, Burgess EF, Park SH, Huddart RA, Ku JH, et al. Erdafitinib versus chemotherapy in fibroblast growth factor receptor-altered advanced or metastatic urothelial cancer after progression on anti-programmed death-(Ligand) 1 therapy: an exploratory analysis of the Asian subpopulation in the THOR phase 3 study. Clin Genitourin Cancer. 2025;23:102376.","journal-title":"Clin Genitourin Cancer"},{"key":"8221_CR11","doi-asserted-by":"crossref","unstructured":"Szklener K, Chmiel P, Michalski A, Mandziuk S. New directions and challenges in targeted therapies of advanced bladder cancer: the role of FGFR inhibitors. Cancers. 2022;14:1416.","DOI":"10.3390\/cancers14061416"},{"key":"8221_CR12","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/cac2.12602","volume":"44","author":"M Noeraparast","year":"2024","unstructured":"Noeraparast M, Krajina K, Pichler R, Niedersuss-Beke D, Shariat SF, Grunwald V, et al. FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies. Cancer Commun (Lond). 2024;44:1189\u2013208.","journal-title":"Cancer Commun (Lond)"},{"key":"8221_CR13","doi-asserted-by":"publisher","first-page":"4613","DOI":"10.1158\/0008-5472.CAN-08-2816","volume":"69","author":"DC Tomlinson","year":"2009","unstructured":"Tomlinson DC, Lamont FR, Shnyder SD, Knowles MA. Fibroblast growth factor receptor 1 promotes proliferation and survival via activation of the mitogen-activated protein kinase pathway in bladder cancer. Cancer Res. 2009;69:4613\u201320.","journal-title":"Cancer Res"},{"key":"8221_CR14","doi-asserted-by":"crossref","unstructured":"Ecke TH, Voss PC, Schlomm T, Rabien A, Friedersdorff F, Barski D, et al. Prediction of response to cisplatin-based neoadjuvant chemotherapy of muscle-invasive bladder cancer patients by molecular subtyping including KRT and FGFR target gene assessment. Int J Mol Sci. 2022;23:7898.","DOI":"10.3390\/ijms23147898"},{"key":"8221_CR15","doi-asserted-by":"publisher","first-page":"831","DOI":"10.3349\/ymj.2016.57.4.831","volume":"57","author":"S Lim","year":"2016","unstructured":"Lim S, Koh MJ, Jeong HJ, Cho NH, Choi YD, Cho do Y, et al. Fibroblast growth factor receptor 1 overexpression is associated with poor survival in patients with resected muscle invasive urothelial carcinoma. Yonsei Med J. 2016;57:831\u20139.","journal-title":"Yonsei Med J"},{"key":"8221_CR16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/path.6060","volume":"259","author":"J Fontugne","year":"2023","unstructured":"Fontugne J, Wong J, Cabel L, Neyret-Kahn H, Karboul N, Maille P, et al. Progression-associated molecular changes in basal\/squamous and sarcomatoid bladder carcinogenesis. J Pathol. 2023;259:455\u201367.","journal-title":"J Pathol"},{"key":"8221_CR17","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/cas.13156","volume":"108","author":"K Matsumoto","year":"2017","unstructured":"Matsumoto K, Umitsu M, De Silva DM, Roy A, Bottaro DP. Hepatocyte growth factor\/MET in cancer progression and biomarker discovery. Cancer Sci. 2017;108:296\u2013307.","journal-title":"Cancer Sci"},{"key":"8221_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/S0022-5347(01)65286-8","volume":"157","author":"EM Rosen","year":"1997","unstructured":"Rosen EM, Joseph A, Jin L, Yao Y, Chau MH, Fuchs A, et al. Urinary and tissue levels of scatter factor in transitional cell carcinoma of bladder. J Urol. 1997;157:72\u201378.","journal-title":"J Urol"},{"key":"8221_CR19","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2312855121","volume":"121","author":"W Jing","year":"2024","unstructured":"Jing W, Wang G, Cui Z, Li X, Zeng S, Jiang X, et al. Tumor-neutrophil cross talk orchestrates the tumor microenvironment to determine the bladder cancer progression. Proc Natl Acad Sci USA. 2024;121:e2312855121.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8221_CR20","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1111\/cas.12662","volume":"106","author":"R Matsumoto","year":"2015","unstructured":"Matsumoto R, Tsuda M, Wang L, Maishi N, Abe T, Kimura T, et al. Adaptor protein CRK induces epithelial-mesenchymal transition and metastasis of bladder cancer cells through HGF\/c-Met feedback loop. Cancer Sci. 2015;106:709\u201317.","journal-title":"Cancer Sci"},{"key":"8221_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-12241-2","volume":"10","author":"WJ Sim","year":"2019","unstructured":"Sim WJ, Iyengar PV, Lama D, Lui SKL, Ng HC, Haviv-Shapira L, et al. c-Met activation leads to the establishment of a TGFbeta-receptor regulatory network in bladder cancer progression. Nat Commun. 2019;10:4349.","journal-title":"Nat Commun"},{"key":"8221_CR22","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/BF00389565","volume":"23","author":"T Morita","year":"1995","unstructured":"Morita T, Shinohara N, Honma M, Tokue A. Establishment and characterization of a new cell line from human bladder cancer (JMSU1). Urol Res. 1995;23:143\u20139.","journal-title":"Urol Res"},{"key":"8221_CR23","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/sj.bjc.6606016","volume":"104","author":"FR Lamont","year":"2011","unstructured":"Lamont FR, Tomlinson DC, Cooper PA, Shnyder SD, Chester JD, Knowles MA. Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. Br J Cancer. 2011;104:75\u201382.","journal-title":"Br J Cancer"},{"key":"8221_CR24","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/bjc.2011.322","volume":"105","author":"J Tanizaki","year":"2011","unstructured":"Tanizaki J, Okamoto I, Sakai K, Nakagawa K. Differential roles of trans-phosphorylated EGFR, HER2, HER3, and RET as heterodimerisation partners of MET in lung cancer with MET amplification. Br J Cancer. 2011;105:807\u201313.","journal-title":"Br J Cancer"},{"key":"8221_CR25","doi-asserted-by":"crossref","unstructured":"Perez-Baena MJ, Cordero-Perez FJ, Perez-Losada J, Holgado-Madruga M. The role of GAB1 in cancer. Cancers. 2023;15:4179.","DOI":"10.3390\/cancers15164179"},{"key":"8221_CR26","doi-asserted-by":"publisher","first-page":"8513","DOI":"10.1128\/MCB.20.22.8513-8525.2000","volume":"20","author":"CR Maroun","year":"2000","unstructured":"Maroun CR, Naujokas MA, Holgado-Madruga M, Wong AJ, Park M. The tyrosine phosphatase SHP-2 is required for sustained activation of extracellular signal-regulated kinase and epithelial morphogenesis downstream from the met receptor tyrosine kinase. Mol Cell Biol. 2000;20:8513\u201325.","journal-title":"Mol Cell Biol"},{"key":"8221_CR27","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.1074\/jbc.M410012200","volume":"280","author":"A Montagner","year":"2005","unstructured":"Montagner A, Yart A, Dance M, Perret B, Salles JP, Raynal P. A novel role for Gab1 and SHP2 in epidermal growth factor-induced Ras activation. J Biol Chem. 2005;280:5350\u201360.","journal-title":"J Biol Chem"},{"key":"8221_CR28","doi-asserted-by":"publisher","first-page":"6187","DOI":"10.1074\/jbc.RA119.010274","volume":"295","author":"RY Zhang","year":"2020","unstructured":"Zhang RY, Yu ZH, Chen L, Walls CD, Zhang S, Wu L, et al. Mechanistic insights explain the transforming potential of the T507K substitution in the protein-tyrosine phosphatase SHP2. J Biol Chem. 2020;295:6187\u2013201.","journal-title":"J Biol Chem"},{"key":"8221_CR29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.ccr.2014.05.019","volume":"26","author":"HJ Lee","year":"2014","unstructured":"Lee HJ, Zhuang G, Cao Y, Du P, Kim HJ, Settleman J. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell. 2014;26:207\u201321.","journal-title":"Cancer Cell"},{"key":"8221_CR30","doi-asserted-by":"publisher","first-page":"30083","DOI":"10.1074\/jbc.M302675200","volume":"278","author":"LS Lock","year":"2003","unstructured":"Lock LS, Frigault MM, Saucier C, Park M. Grb2-independent recruitment of Gab1 requires the C-terminal lobe and structural integrity of the Met receptor kinase domain. J Biol Chem. 2003;278:30083\u201390.","journal-title":"J Biol Chem"},{"key":"8221_CR31","doi-asserted-by":"publisher","first-page":"15376","DOI":"10.1073\/pnas.0702555104","volume":"104","author":"U Schaeper","year":"2007","unstructured":"Schaeper U, Vogel R, Chmielowiec J, Huelsken J, Rosario M, Birchmeier W. Distinct requirements for Gab1 in Met and EGF receptor signaling in vivo. Proc Natl Acad Sci USA. 2007;104:15376\u201381.","journal-title":"Proc Natl Acad Sci USA"},{"key":"8221_CR32","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/384173a0","volume":"384","author":"KM Weidner","year":"1996","unstructured":"Weidner KM, Di Cesare S, Sachs M, Brinkmann V, Behrens J, Birchmeier W. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature. 1996;384:173\u20136.","journal-title":"Nature"},{"key":"8221_CR33","doi-asserted-by":"publisher","first-page":"9479","DOI":"10.1158\/0008-5472.CAN-08-1643","volume":"68","author":"S Yano","year":"2008","unstructured":"Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008;68:9479\u201387.","journal-title":"Cancer Res"},{"key":"8221_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16212-w","volume":"11","author":"R Vander Velde","year":"2020","unstructured":"Vander Velde R, Yoon N, Marusyk V, Durmaz A, Dhawan A, Miroshnychenko D, et al. Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures. Nat Commun. 2020;11:2393.","journal-title":"Nat Commun"},{"key":"8221_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.111662","volume":"28","author":"O Petrenko","year":"2025","unstructured":"Petrenko O, Kirillov V, D\u2019Amico S, Reich NC. Intratumor heterogeneity in KRAS signaling shapes treatment resistance. iScience. 2025;28:111662.","journal-title":"iScience"},{"key":"8221_CR36","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","volume":"166","author":"MA Nieto","year":"2016","unstructured":"Nieto MA, Huang RY, Jackson RA, Thiery JP. Emt: 2016. Cell. 2016;166:21\u201345.","journal-title":"Cell"},{"key":"8221_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-017-0012-z","volume":"3","author":"GM Wahl","year":"2017","unstructured":"Wahl GM, Spike BT. Cell state plasticity, stem cells, EMT, and the generation of intra-tumoral heterogeneity. NPJ Breast Cancer. 2017;3:14.","journal-title":"NPJ Breast Cancer"},{"key":"8221_CR38","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","volume":"37","author":"A Marusyk","year":"2020","unstructured":"Marusyk A, Janiszewska M, Polyak K. Intratumor heterogeneity: the rosetta stone of therapy resistance. Cancer Cell. 2020;37:471\u201384.","journal-title":"Cancer Cell"},{"key":"8221_CR39","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1038\/s43018-023-00595-y","volume":"4","author":"A Perez-Gonzalez","year":"2023","unstructured":"Perez-Gonzalez A, Bevant K, Blanpain C. Cancer cell plasticity during tumor progression, metastasis and response to therapy. Nat Cancer. 2023;4:1063\u201382.","journal-title":"Nat Cancer"},{"key":"8221_CR40","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202201247R","volume":"37","author":"X Li","year":"2023","unstructured":"Li X, Li Y, Liu B, Chen L, Lyu F, Zhang P, et al. P4HA2-mediated HIF-1alpha stabilization promotes erdafitinib-resistance in FGFR3-alteration bladder cancer. FASEB J. 2023;37:e22840.","journal-title":"FASEB J"},{"key":"8221_CR41","doi-asserted-by":"publisher","first-page":"4586","DOI":"10.1158\/1078-0432.CCR-23-1283","volume":"29","author":"BJ Guercio","year":"2023","unstructured":"Guercio BJ, Sarfaty M, Teo MY, Ratna N, Duzgol C, Funt SA, et al. Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience. Clin Cancer Res. 2023;29:4586\u201395.","journal-title":"Clin Cancer Res"},{"key":"8221_CR42","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1158\/2159-8290.CD-22-1441","volume":"13","author":"F Facchinetti","year":"2023","unstructured":"Facchinetti F, Hollebecque A, Braye F, Vasseur D, Pradat Y, Bahleda R, et al. Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer. Cancer Discov. 2023;13:1998\u20132011.","journal-title":"Cancer Discov"},{"key":"8221_CR43","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider CA, Rasband WS, Eliceiri KW. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9:671\u20135.","journal-title":"Nat Methods"},{"key":"8221_CR44","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fernandez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7. 16878.","journal-title":"Sci Rep"},{"key":"8221_CR45","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171:540\u201356 e525.","journal-title":"Cell"},{"key":"8221_CR46","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401\u20134.","journal-title":"Cancer Discov"},{"key":"8221_CR47","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.","journal-title":"Sci Signal"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08221-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08221-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08221-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,28]],"date-time":"2025-11-28T16:02:34Z","timestamp":1764345754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-08221-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,28]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["8221"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-08221-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6348619\/v1","asserted-by":"object"}]},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,28]]},"assertion":[{"value":"31 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were approved by the Fukushima Medical University School of Medicine Animal Care and Use Committee (permission number: 2024076). All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"868"}}